Chinese hamster ovary (CHO) cells represent the most frequently applied host cell system for industrial manufacturing of recombinant protein therapeutics. Generating and identifying high producing clones in a fast and efficient way such that they do not lose their expression capability over time has been a major focus of the industry.
Using cytogentic analysis combined with next-generation sequencing technology and proprietary bioinformatic tools called SUREscan, provide us with a unique ability to quickly analyze the whole genome of any generated cell line. Our data show that phenotypic changes in growth behavior and metabolism typically cuased by cellular stress such as adaptation to a different media are associated with a rise in single nucleotide polymorphisms (SNPs). However, karyotype analysis of a large number of research cell banks (RCBs) revealed our CHO lineage is chromosomally stable indicating that the critical stages of a call line production platform do not induce chromosomalchanges. This contrasts with previous studies that have sown large chromosomal rearrangements in CHO cell lines.
Recombinant therapeutic protein production processes must guarantee a sufficiently small variability in the product quality. To keep this variability low, it is critical to run the process in a totally reproducible way. This requires controlling all cultivation parameters. The use of new analyzers, generating new data sets, besides cultivation parameters (e.g. viable cell density, metabolite concentrations) is a desirable way to innovate bioprocesses. The advent of Next-generation Sequencing (NGS) has led to the ability of using genome information to find reasons for variability. Research Cell Banks (RCBs) are not necessarily cell populations with identical genomes or single integration sites even though they arise from a single isolated cell. These mixed populations can lead to unacceptable manufacturing variability. Selexis’ SUREscan™, consisting of the detailed CHO-M genomic map and proprietary bioinformatics tools, decreases manufacturing risks by ensuring transgene integrity in RCBs and by surveying for the emergence of deleterious mutations either in the transgene sequence or in genes that are important for cell survival at a yet unknown resolution.
In an effort to improve product yield of mammalian cell lines, we have previously demonstrated that our proprietary DNA elements, Selexis Genetic Elements (SGEs), increase the transcription of a given transgene1, thus boosting the overall expression of a therapeutic protein drug in mammalian cells. However, there are additional cellular bottlenecks, notably in the molecular machineries of the secretory pathways. Most importantly, mammalian cells have some limitations in their intrinsic capacity to manage high level of protein synthesis as well as folding recombinant proteins. These bottlenecks often lead to increased cellular stress and, therefore, low production rates. Our specific approach involves CHO cell line engineering. We constructed a CHO-M library based upon the CHO-M genome and transcriptome and using unique proprietary transposon vectors harboring SGE DNA elements to compensate for rate-limiting factors. This CHO-Mplus library displays a diversity of greater than 1×107 auxiliary proteins involved in secretory pathway machineries and cellular metabolism. We show that our CHO-Mplus library enabled the selection of a clonal cell line expressing 10 fold more product by comparison to standard approaches.
The development of new mammalian expression platforms represents an ongoing need for advancing biophar-maceuticals towards human clinical trials.
In an effort to address this issue, we have developed new solutions for more efficient identification of individ-ual protein candidates in stably trans-fected CHO cells. We have shown that the combination of high transfec-tion efficiency with the presence of chromatin structural elements (Selexis Genetic Element) in the ex-pression vectors results in higher effi-ciency of expression and stability of engineered cells. This allows the pro-tein of interest to be readily secreted and recovered in high yield from the medium. Based on this approach, combinatorial human antibody librar-ies are generated in CHO cells to al-low the identification of the most promising human antibody for binding and expression.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2021 Selexis SA. All Rights Reserved.
